atai Life Sciences (ATAI)
(Delayed Data from NSDQ)
$1.81 USD
-0.04 (-2.16%)
Updated Apr 22, 2024 11:54 AM ET
After-Market: $1.93 +0.12 (6.63%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
ATAI 1.81 -0.04(-2.16%)
Will ATAI be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ATAI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ATAI
Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice
Is Align Technology (ALGN) Stock Outpacing Its Medical Peers This Year?
ATAI: What are Zacks experts saying now?
Zacks Private Portfolio Services
Aveanna Healthcare (AVAH) Reports Q4 Loss, Tops Revenue Estimates
LifeStance Health Group (LFST) Reports Q4 Loss, Tops Revenue Estimates
Elevance Health (ELV) & Verizon Partner to Bring Health Equity
Other News for ATAI
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'
Rising High: Exclusive talk with cannabis market research firm BDSA
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
Atai Life announces publication of Beckley Psytech's Phase 1 study of BPL-003